1,5-二氯-3-甲基戊烷 | 56702-89-7

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氯化物
• 中文名称: 1,5-二氯-3-甲基戊烷
• 英文名称: mechloroethamine
• 英文别名: 1.5-Dichlor-3-methyl-pentan；1,5-dichloro-3-methyl-pentane；Pentane, 1,5-dichloro-3-methyl-；1,5-dichloro-3-methylpentane
• CAS: 56702-89-7
• 化学式: C₆H₁₂Cl₂
• mdl: MFCD00039382
• 分子量: 155.067
• InChiKey: ITPYJYKCTJIIJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1,5-二氯-3-甲基戊烷 在 NaCN 作用下， 以 二甲基亚砜 为溶剂， 生成 4-methylheptanedinitrile
  参考文献：
  名称：

  Novel cyclopentane derivatives

  摘要：

  本发明涉及A系列前列腺素的新型非天然存在的10,11-二氢衍生物，以及它们的制备方法。本发明的化合物具有抗前列腺素作用，可用作药物，用于抑制或抑制前列腺素的药理特性。

  公开号：

  US03984459A1

文献信息

• Pyrido [2,1-a] isoquinoline derivatives
  申请人：——

  公开号：US20040259903A1

  公开（公告）日：2004-12-23

  The present invention provides compounds of formula (I) 1 wherein R 1 , R 2 , R 3 and R 4 are as indicated in the description, or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明提供了式（I）的化合物，其中R1、R2、R3和R4如描述中所示，或其药学上可接受的盐。这些化合物可用于治疗与DPP-IV相关的疾病，如糖尿病，特别是非胰岛素依赖型糖尿病和糖耐量受损。
• 1-, and 1,1-disubstituted-6-substituted-2-carbamimidoyl-1-carbadethiapen-2-em-3-carboxylic acids, a process for preparing and an antibiotic composition containing the same
  申请人：Merck & Co., Inc.

  公开号：EP0071908A1

  公开（公告）日：1983-02-16

  Disclosed are 1-, and 1,1-disubstituted-6-substituted-2-carbamimidoyl-1-carbadethiapen-2-em-3-carboxylic acids having the structure: wherein R9 and R10 are, inter alia, hydrogen R9 and R10 are not both hydrogen) alkyl, cycloalkyl, aryl, and aralkyl; R9 and R10 may be joined; R6 and R7 are, inter alia, independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, aralkyl; A is a direct, single bond connecting the indicated S and C atoms, or A is a cyclic or acylic connecting group selected, inter alia, from alkyl, cycloalkyl, aryl, heteroaryl, heteroalkyl; R1 and R2, which define the carbamimidoyl function, are, inter alia, independently selected from hydrogen, alkyl, aryl; additionally, said carbamimidoyl is characterized by cyclic structures achieved by the joinder of the two nitrogen atoms via their substituents and by their joinder to connecting group A; additionally, "carbami- midiums" are disclosed by quarternization of on of the nitrogen atoms of said carbamimidoyl. Such compounds as well as their pharmaceutically acceptable salt, ester and amide derivates are useful as antibiotics. Also disclosed are processes for the preparation of such compounds and pharmaceutical compositions comprising such compounds.

  公开了具有以下结构的1-和1,1-二取代-6-取代-2-氨基甲酰亚胺基-1-碳二硫杂庚烯-2-em-3-羧酸： 其中 R9 和 R10 除其他外，是氢 R9 和 R10 不都是氢）烷基、环烷基、芳基和芳烷基；R9 和 R10 可以连接；R6 和 R7 除其他外，独立地选自氢、烷基、烯基、芳基、芳烷基组成的组；A 是连接所指 S 原子和 C 原子的直接单键，或者 A 是除其他外选自烷基、环烷基、芳基、杂芳基、杂烷基的环状或酰基连接基团；定义氨基甲酰亚胺官能团的 R1 和 R2 除其他外，独立地选自氢、烷基、芳基；此外，所述氨基甲酰亚胺的特征是通过取代基连接两个氮原子以及连接基 A 实现环状结构；此外，通过对所述氨基甲酰亚胺的一个氮原子进行仲氨化，公开了 "氨基甲酰亚胺"。此类化合物及其药学上可接受的盐、酯和酰胺衍生物可用作抗生素。此外，还公开了制备此类化合物和含有此类化合物的药物组合物的工艺。
• 6-(1-Hydroxyethyl)-2-SR8-1-methyl-1-carbadethiapen-2-em-3-carboxylic acid esters
  申请人：Merck & Co., Inc.

  公开号：EP0113101A1

  公开（公告）日：1984-07-11

  Diselosed are 6-[1-hydroxyethyl)-2-SR5-1-methyl-1-carbadethiapen-2-em-3-carboxylic acid esters (I) which are oralfy active antibiotics: wherein: R is a pharmaceutically acceptable ester moiety consistent with oral delivery; and R' is substituted or unsubstituted: alkyl, alkenyl, alkynyl, or cyclic alkyl, alkenyl, alkynyl, having 1-6 carbon atoms, aryl such as phenyl or heteroaryl such as pyridyl; wherein the substituent or substituents are selected from: phenyl, pyridyl, cyano, fluoro, chloro, hydroxy, alkylthio such as methylthio, arylthio such as phenylthio, methoxy, phenoxy, alkoxycarbonyl such as methoxycarbonyl, acetoxyl, N-methylcarbamoyl, N-methylcarbamoyloxy and N-acylamino. Also disclosed are processes for the preparation of such compounds and pharmaceutical compositions comprising such compounds.

  分离出的 6-[1-羟乙基]-2-SR5-1-甲基-1-巴豆硫杂庚烯-2-em-3-羧酸酯 (I) 是一种具有或半活性的抗生素： 其中R是符合口服给药的药学上可接受的酯基；R'是取代或未取代的：烷基、烯基、炔基，或具有 1-6 个碳原子的环状烷基、烯基、炔基，芳基如苯基或杂芳基如吡啶基；其中的取代基或多个取代基选自：苯基、吡啶基、氰基、氟基、氯基、羟基、烷硫基如甲硫基、芳硫基如苯硫基、甲氧基、苯氧基、烷氧基羰基如甲氧基羰基、乙酰氧基、N-甲基氨基甲酰基、N-甲基氨基甲酰氧基和 N-酰氨基。 还公开了制备此类化合物的工艺和包含此类化合物的药物组合物。
• A process for producing alicyclic hydrazine derivatives, tetra-hydropyridazine and hexahydropyridazine
  申请人：JAPAN HYDRAZINE CO., LTD.

  公开号：EP0850930A2

  公开（公告）日：1998-07-01

  The present invention relates to a process for producing alicyclic hydrazine derivatives, tetrahydropyridazine and hexahydropyridazine which are useful as intermediate starting materials such as medicines and agricultural chemicals. Especially, the present invention provides; a process for producing an alicyclic hydrazine derivative or its hydrohalogenic acid salt, which comprises reacting a hydrazine hydrohalogenic acid salt with a doil compound or an alicyclic ether compound in the presence of an excessive inorganic acid existing in a free form or in the form of an acid addition salt; a process for producing tetrahydropyridazine from 1-aminopyrrolidine, which comprises oxidizing 1-aminopyrrolidine with an oxidizing agent to form tetrahydropyridazine; and a process for producing hexahydropyridazine, which comprises oxidizing 1-aminopyrrolidine with an oxidizing agent, synthesizing tetrahydropyridazine, and thereafter, hydrogenating the tetrahydropyridazine in the presence of a base.

  本发明涉及一种生产脂环族肼衍生物、四氢哒嗪和六氢哒嗪的工艺，这些衍生物可用作药物和农药等中间起始原料。特别是，本发明提供了 一种生产脂环族肼衍生物或其氢卤酸盐的工艺，包括在以游离形式或以酸加成盐形式存在的过量无机酸的存在下，使肼氢卤酸盐与多伊尔化合物或脂环族醚化合物反应； 一种用 1-氨基吡咯烷生产四氢哒嗪的工艺，其中包括用氧化剂氧化 1-氨基吡咯烷以形成四氢哒嗪；以及 一种生产六氢哒嗪的工艺，包括用氧化剂氧化 1-氨基吡咯烷，合成四氢哒嗪， 然后在碱存在下氢化四氢哒嗪。
• A process for producing alicyclic hydrazine derivatives.
  申请人：JAPAN HYDRAZINE CO., LTD.

  公开号：EP0850930B1

  公开（公告）日：2001-10-31

表征谱图